Medically refractory neurosarcoidosis treated with infliximab

被引：34

作者：

Pereira, J. ^{[1
]}

Anderson, N. E. ^{[2
]}

McAuley, D. ^{[2
]}

Bergin, P. ^{[2
]}

Kilfoyle, D. ^{[2
]}

Fink, J. ^{[3
]}

机构：

[1] Univ Auckland, Dept Med, Auckland 1142, New Zealand

[2] Auckland City Hosp, Dept Neurol, Auckland, New Zealand

[3] Christchurch Hosp, Dept Neurol, Christchurch, New Zealand

来源：

INTERNAL MEDICINE JOURNAL | 2011年 / 41卷 / 04期

关键词：

sarcoidosis; infliximab; monoclonal antibody; tumour necrosis; factor-alpha; anti-inflammatory agent; NERVOUS-SYSTEM SARCOIDOSIS; DIAGNOSIS;

D O I：

10.1111/j.1445-5994.2011.02457.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Neurosarcoidosis can worsen despite standard immunosuppressive therapy, a situation for which there is no established medical management. We present three cases of medically refractory neurosarcoidosis treated with infliximab. All three patients showed a clinical response to this treatment and side effects were limited. A summary of reported cases of neurosarcoidosis treated with infliximab is included. This case series supports a role for infliximab in the treatment of patients with medically refractory neurosarcoidosis.

引用

页码：354 / 357

页数：4

共 16 条

[1] Refractory neurosarcoidosis: A dramatic response to infliximab [J].